149 related articles for article (PubMed ID: 32815366)
1. Rational Design of Suprastat: A Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models.
Noonepalle S; Shen S; Ptáček J; Tavares MT; Zhang G; Stránský J; Pavlíček J; Ferreira GM; Hadley M; Pelaez G; Bařinka C; Kozikowski AP; Villagra A
J Med Chem; 2020 Sep; 63(18):10246-10262. PubMed ID: 32815366
[TBL] [Abstract][Full Text] [Related]
2. PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
Gawel JM; Shouksmith AE; Raouf YS; Nawar N; Toutah K; Bukhari S; Manaswiyoungkul P; Olaoye OO; Israelian J; Radu TB; Cabral AD; Sina D; Sedighi A; de Araujo ED; Gunning PT
Eur J Med Chem; 2020 Sep; 201():112411. PubMed ID: 32615502
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Novel Histone Deacetylase 6 (HDAC6) Inhibitors with Enhanced Antitumor Immunity of Anti-PD-L1 Immunotherapy in Melanoma.
Peng X; Li L; Chen J; Ren Y; Liu J; Yu Z; Cao H; Chen J
J Med Chem; 2022 Feb; 65(3):2434-2457. PubMed ID: 35043615
[TBL] [Abstract][Full Text] [Related]
4. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
5. Exploring Structural Determinants of Inhibitor Affinity and Selectivity in Complexes with Histone Deacetylase 6.
Osko JD; Porter NJ; Narayana Reddy PA; Xiao YC; Rokka J; Jung M; Hooker JM; Salvino JM; Christianson DW
J Med Chem; 2020 Jan; 63(1):295-308. PubMed ID: 31793776
[TBL] [Abstract][Full Text] [Related]
6. Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype.
Olaoye OO; Watson PR; Nawar N; Geletu M; Sedighi A; Bukhari S; Raouf YS; Manaswiyoungkul P; Erdogan F; Abdeldayem A; Cabral AD; Hassan MM; Toutah K; Shouksmith AE; Gawel JM; Israelian J; Radu TB; Kachhiyapatel N; de Araujo ED; Christianson DW; Gunning PT
J Med Chem; 2021 Mar; 64(5):2691-2704. PubMed ID: 33576627
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
Vögerl K; Ong N; Senger J; Herp D; Schmidtkunz K; Marek M; Müller M; Bartel K; Shaik TB; Porter NJ; Robaa D; Christianson DW; Romier C; Sippl W; Jung M; Bracher F
J Med Chem; 2019 Feb; 62(3):1138-1166. PubMed ID: 30645113
[TBL] [Abstract][Full Text] [Related]
8. Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
Ojha R; Nepali K; Chen CH; Chuang KH; Wu TY; Lin TE; Hsu KC; Chao MW; Lai MJ; Lin MH; Huang HL; Chang CD; Pan SL; Chen MC; Liou JP
Eur J Med Chem; 2020 Mar; 190():112086. PubMed ID: 32058238
[TBL] [Abstract][Full Text] [Related]
9. HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics.
Laino AS; Betts BC; Veerapathran A; Dolgalev I; Sarnaik A; Quayle SN; Jones SS; Weber JS; Woods DM
J Immunother Cancer; 2019 Feb; 7(1):33. PubMed ID: 30728070
[TBL] [Abstract][Full Text] [Related]
10. Quinazolin-2,4-dione-Based Hydroxamic Acids as Selective Histone Deacetylase-6 Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Yu CW; Hung PY; Yang HT; Ho YH; Lai HY; Cheng YS; Chern JW
J Med Chem; 2019 Jan; 62(2):857-874. PubMed ID: 30525585
[TBL] [Abstract][Full Text] [Related]
11. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.
Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J
Front Immunol; 2020; 11():590072. PubMed ID: 33329575
[TBL] [Abstract][Full Text] [Related]
12. Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects
He F; Chou CJ; Scheiner M; Poeta E; Yuan Chen N; Gunesch S; Hoffmann M; Sotriffer C; Monti B; Maurice T; Decker M
J Med Chem; 2021 Apr; 64(7):3794-3812. PubMed ID: 33769811
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models.
Shen S; Hadley M; Ustinova K; Pavlicek J; Knox T; Noonepalle S; Tavares MT; Zimprich CA; Zhang G; Robers MB; Bařinka C; Kozikowski AP; Villagra A
J Med Chem; 2019 Sep; 62(18):8557-8577. PubMed ID: 31414801
[TBL] [Abstract][Full Text] [Related]
14. Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated.
Géraldy M; Morgen M; Sehr P; Steimbach RR; Moi D; Ridinger J; Oehme I; Witt O; Malz M; Nogueira MS; Koch O; Gunkel N; Miller AK
J Med Chem; 2019 May; 62(9):4426-4443. PubMed ID: 30964290
[TBL] [Abstract][Full Text] [Related]
15. Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups.
Reßing N; Sönnichsen M; Osko JD; Schöler A; Schliehe-Diecks J; Skerhut A; Borkhardt A; Hauer J; Kassack MU; Christianson DW; Bhatia S; Hansen FK
J Med Chem; 2020 Sep; 63(18):10339-10351. PubMed ID: 32803970
[TBL] [Abstract][Full Text] [Related]
16. Investigation of non-hydroxamate scaffolds against HDAC6 inhibition: A pharmacophore modeling, molecular docking, and molecular dynamics simulation approach.
Zeb A; Park C; Son M; Rampogu S; Alam SI; Park SJ; Lee KW
J Bioinform Comput Biol; 2018 Jun; 16(3):1840015. PubMed ID: 29945500
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
Kassab SE; Mowafy S; Alserw AM; Seliem JA; El-Naggar SM; Omar NN; Awad MM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1062-1077. PubMed ID: 31072216
[TBL] [Abstract][Full Text] [Related]
18. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
[TBL] [Abstract][Full Text] [Related]
19. Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth.
Bergman JA; Woan K; Perez-Villarroel P; Villagra A; Sotomayor EM; Kozikowski AP
J Med Chem; 2012 Nov; 55(22):9891-9. PubMed ID: 23009203
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel benzohydroxamate-based histone deacetylase 6 (HDAC6) inhibitors with the ability to potentiate anti-PD-L1 immunotherapy in melanoma.
Peng X; Yu Z; Surineni G; Deng B; Zhang M; Li C; Sun Z; Pan W; Liu Y; Liu S; Yu B; Chen J
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2201408. PubMed ID: 37096557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
